279 citations
,
June 1990 in “Journal of Clinical Oncology” The study found that for positive-node breast cancer patients aged 50 and older, adding chemotherapy to tamoxifen significantly improved disease-free survival compared to tamoxifen alone.
49 citations
,
December 1997 in “Urology” This study found that low-dose tamoxifen may effectively treat painful gynecomastia in patients receiving flutamide and finasteride for advanced prostate cancer.
24 citations
,
November 2013 in “British Journal of Dermatology” This study found that chemotherapy in female breast cancer patients caused significant early hair loss, which began to recover three months after completion, whereas tamoxifen did not affect hair growth.
23 citations
,
February 2004 in “Clinical and Experimental Ophthalmology” This case report describes a 68-year-old woman with metastatic breast cancer who experienced significant improvement in visual acuity after stopping tamoxifen, which was associated with bilateral optic neuropathies.
19 citations
,
June 2001 in “Annals of Internal Medicine” This case report describes total alopecia in a 53-year-old woman after 13 months of tamoxifen treatment for breast cancer, with normal hair distribution maintained elsewhere.
16 citations
,
October 2012 in “British Journal of Dermatology” Chemotherapy can cause significant hair thinning and changes in hair texture, while tamoxifen has a smaller effect.
15 citations
,
May 1997 in “Annals of Internal Medicine” This case report describes a patient with breast cancer who developed female androgenetic alopecia after starting tamoxifen therapy.
8 citations
,
September 2015 in “Journal of the European Academy of Dermatology and Venereology” This study observed that hair and scalp sensations were significantly more common and intense in chemotherapy patients compared to those receiving tamoxifen, with sensations ceasing after 11 weeks.
5 citations
,
August 2012 in “Journal of Dermatology” This report presents a case where female pattern hair loss might be linked to tamoxifen use, with increased androgen receptor expression observed in the affected scalp area.
February 2024 in “PloS one” This study found that certain nutraceuticals did not interfere with tamoxifen's inhibition of estrogen in breast cancer cells and may enhance its effects, suggesting potential as an adjuvant therapy for hair loss in patients undergoing endocrine therapy.
February 2022 in “Research Square (Research Square)” In this cell-based study, researchers found that certain nutraceuticals combined with tamoxifen may influence estrogen receptor expression, potentially offering a protective effect and promoting hair growth during breast cancer therapy.
December 2021 in “Research Square (Research Square)” This study suggests that certain nutraceuticals may enhance the inhibitory effects of tamoxifen on estrogen in breast cancer cells and potentially offer protective benefits for hair growth in patients undergoing endocrine therapy.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” This study explored the effects of various nutraceutical ingredients on breast cancer cell lines but found no conclusive information regarding their interaction with tamoxifen therapy.
January 2015 in “Journal of pediatric endocrinology & metabolism/Journal of pediatric endocrinology and metabolism” In this case report, tamoxifen-induced hirsutism was observed in a young girl with McCune-Albright syndrome shortly after starting treatment.
May 2013 in “UTUPub (University of Turku)” This study suggests that adding androgens to menopausal hormone therapy may reduce breast cancer risk by counteracting estrogen-driven proliferation in postmenopausal breast tissue.
This study found that tamoxifen citrate markedly inhibited castration-induced diffuse hair growth in castrated female mice, while cyproterone showed only slight inhibition in male mice.
January 2004 in “Indian Journal of Nephrology” 
March 2026 in “Journal of Personalized Medicine” In this study involving South African breast cancer patients, researchers identified certain genetic variations in cytochrome P450 and other enzymes potentially linked to differences in tamoxifen treatment outcomes, suggesting a need for more comprehensive pharmacogenomic studies to optimize therapy in African populations.
This study found that a significant portion of counterfeit drugs seized among bodybuilders did not match their labels, with many containing undeclared anabolic steroids or other unexpected active ingredients.
514 citations
,
February 2011 in “International journal of women's health” This review discusses treatments for various symptoms of polycystic ovary syndrome, including lifestyle changes, medical, and surgical interventions, but does not present new clinical results.
184 citations
,
November 2014 in “Developmental Cell” This study identifies a bipotent stem cell in adult hair follicles that self-renews and contributes to dermal sheath and papilla cell populations, potentially aiding hair regrowth after injury, disease, or aging.
76 citations
,
June 2018 in “EMBO Reports” This study demonstrates that YAP and TAZ are essential for initiating basal and squamous cell carcinomas in mice, and suggests targeting these pathways could be beneficial for treating skin cancers.
67 citations
,
April 2018 in “JAMA Dermatology” This study found that endocrine therapy for breast cancer is associated with a pattern of hair loss similar to androgenetic alopecia, negatively impacting quality of life despite mild severity.
67 citations
,
October 2005 in “Annals of Oncology” This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.
48 citations
,
September 2013 in “Oncologist” This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.
43 citations
,
April 2010 in “Developmental Biology” In this study, researchers observed that the sebaceous gland niche in mice allows for Wnt-induced hair follicle differentiation, unlike the non-permissive bulge.
29 citations
,
January 2010 in “Methods in Enzymology” This review discusses five genetic fate mapping methods used to study cell behaviors during development and regeneration, detailing the necessary tools and considerations without reporting new experimental results.
23 citations
,
February 2020 in “PLOS genetics” This study found that biallelic LSS mutations lead to congenital hypotrichosis and cataracts, with each tissue-specific loss of function observed in mouse models.
20 citations
,
February 2004 in “Clinical and Experimental Ophthalmology” This paper presents two cases of rare intraorbital ophthalmic artery aneurysms associated with arteriovenous malformations and discusses their clinical presentation, pathogenesis, and management, but reports no new clinical outcomes.
16 citations
,
March 2019 in “Experimental dermatology” This study found that injury affects the behavior of hair follicle dermal stem cells, steering them towards recruitment into the dermal papilla, a shift influenced by the hair cycle stage.